Rokote Laboratories Finland Oy is focused on developing innovative vaccine technologies, particularly the FINCoVac and its second-generation counterpart, FINCoVac 2.1, aimed at combating COVID-19. The FINCoVac vaccine is administered nasally, which is intended to elicit a broader immune response compared to traditional intramuscular vaccines, as it targets the airways where the virus initially infects. This approach is particularly relevant given the rapid mutation of the SARS-CoV-2 virus, which poses ongoing challenges for vaccine efficacy. The company’s research is supported by collaborations with esteemed institutions such as the University of Helsinki and the University of Eastern Finland, leveraging long-term research expertise to inform their vaccine development.

The company is also preparing for clinical trials, which are anticipated to begin by late summer 2024, following the necessary regulatory approvals. These trials will involve healthy adult volunteers, both those who have been fully vaccinated with other COVID-19 vaccines and a smaller group of unvaccinated individuals. The FINCoVac 2.1 vaccine is designed not only to provide robust protection against emerging variants but also to serve as a potential booster for individuals already vaccinated. Furthermore, the underlying vaccine technology has the potential to be adapted for developing vaccines against other viral infections, highlighting the versatility and future applicability of their research efforts.

Finland

Rokote Laboratories Finland Oy is a Finnish vaccine development company.
We are developing the Finnish COVID-19 vaccine.

Rokote Laboratories Finland Oy

Company Details